RESILIA tissue offers enhanced anti-calcification technology that will potentially allow the valve to last longer than conventional bioprosthetic valves.
Welcome
A key challenge with pericardial tissue is structural valve deterioration (SVD), much of which is due to calcium buildup. RESILIA tissue is transformed to resist calcification differently.
Proprietary tissue integrity preservation technology mitigates residual aldehydes. This enables dry storage that simplifies handing.
Seven-year data from the COMMENCE aortic trial represent the longest follow-up after AVR with RESILIA tissue in a large IDE trial utilizing an independent clinical events committee and echocardiography core laboratory.
Click below to find media assets for download on the COMMENCE 7-year study results of RESILIA
tissue valves.
Explore our current products with RESILIA tissue. Click below to find media assets available for download for the INSPIRIS RESILIA aortic valve, KONECT RESILIA aortic valved conduit, and MITRIS RESILIA mitral valve.